Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes

IVIG is a safe and effective treatment for JDM, particularly in patients with refractory or skin-predominant disease. Given the retrospective nature of the study and absence of a control group, causal inferences should be made with caution; however, our findings support IVIG as a valuable option in real-life management. These findings support the use of IVIG as part of an individualized treatment approach; however, further prospective, controlled studies are needed to optimize its role in long-term disease management.